SermorelinGHRH(1-29) · the physiologic GH-releasing analog
A synthetic copy of the first 29 amino acids of the body's own growth-hormone-releasing hormone (GHRH). Instead of injecting growth hormone directly, sermorelin signals the pituitary to release its own GH in natural pulses. It is the only GH secretagogue in this atlas with a real FDA-approval history — marketed as Geref for childhood growth-hormone deficiency until it was discontinued for commercial reasons. Most modern adult "wellness" use is off-label, compounded, and experimental; it is prohibited in sport under WADA category S2.
The biologically active N-terminal 1–29 fragment of human GHRH, functioning as a GHRH-receptor agonist on anterior pituitary somatotrophs. Unlike the ghrelin-receptor GHRPs, it drives the Gs–cAMP–PKA arm of GH release, and because the response remains under somatostatin negative feedback it is self-limiting and physiologic. Clinical pharmacology reports a short half-life (~11–12 min), SC peak in 5–20 min, and ~6% SC bioavailability. Nightly dosing in older adults raised IGF-1 and IGFBP-3 within weeks. Best-supported uses are diagnostic GH-reserve testing and pediatric growth contexts.
Sermorelin — Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH₂ (C₁₄₉H₂₄₆N₄₄O₄₂S, MW ≈ 3357.9 Da, CAS 86168-78-7, PubChem CID 16132413) — the shortest fully functional GHRH fragment. KEGG identifies it as a GHRH analog targeting GHRHR, used as a diagnostic/pituitary-function agent and GHRH-receptor agonist. Modifying GRF(1-29) at residues 2/8/15/27 yields MOD GRF(1-29) — the longer-acting backbone behind CJC-1295. Feedback-preserved axis dependence, short half-life, and ~6% SC bioavailability define its translational boundary.
~11 minHalf-life · IV/SC · label-derived
~6%SC absolute bioavailability
1990/97FDA approvals (Geref Dx / Geref Rx)
S2WADA class · prohibited at all times
Status
FDA-approved 1990/97 · discontinued 2008 · now compounded
Sermorelin is the GHRH-receptor arm of the GH-secretagogue world — the "clean" upstream signal that asks the pituitary to make its own GH, kept in check by the body's own feedback. It stands apart from every other peptide in this cluster by having a genuine FDA-approval history (Geref). That history is for pediatric and diagnostic use, however; the modern adult anti-aging market runs on much thinner evidence.
🩺
Primary use case
Dx + pediatric
Historically used to stimulate endogenous GH in children with GH-deficiency growth failure and for pituitary GH-reserve testing. Grade B/D.
🔑
Mechanism headline
GHRH-R
A GHRH-receptor agonist on anterior pituitary somatotrophs that increases endogenous GH release via the Gs–cAMP–PKA pathway. Grade B.
📊
Strongest evidence tier
Human + Rx history
Human pediatric and adult studies show GH/IGF-1 axis activation; modern large adult outcome trials are limited. Grade B.
♻️
Distinctive feature
Feedback-preserved
Because it depends on pituitary capacity and somatostatin feedback, it is theoretically less likely than direct GH to produce supraphysiologic levels — though long-term safety advantage is unproven. Grade D/P.
💉
Typical dose
200–300 µg
Label-derived practice dosing centers on 200–300 µg once nightly SC; pediatric research used weight-based µg/kg designs. Grade D/B.
⏱️
Half-life
~11 min
Short half-life (~11–12 min) and ~6% SC bioavailability — the reason MOD GRF(1-29)/CJC-1295 were engineered for longer action. Grade B.
⚠️
Key risk
IGF-1 · thyroid
Avoid in hypersensitivity; caution with active malignancy, intracranial lesions, uncontrolled metabolic/thyroid disease, pregnancy/lactation. Grade D.
🏛️
Regulatory status
Was approved
FDA-approved as Geref (Dx 1990, Rx 1997); discontinued 2008 for commercial — not safety — reasons; now compounded off-label. Grade D.
02 · Mechanism of action
How sermorelin drives a physiologic GH pulse.
Sermorelin is the body's own GHRH signal, shortened to its active core. It binds the GHRH receptor on pituitary somatotrophs and switches on the cAMP/PKA pathway to release stored GH — but only within the limits set by somatostatin and IGF-1 negative feedback. That feedback dependence is its defining property: it amplifies a natural rhythm rather than overriding it, which is also why an intact pituitary is required for it to work.
Grade B
🔑
1 · GHRH-receptor activation on somatotrophs
Sermorelin tells the pituitary to release the body's own growth hormone rather than supplying growth hormone directly.
Clinical significance: The target is the GHRH receptor on anterior pituitary somatotroph cells; a GH pulse follows when receptor responsiveness and pituitary reserve are intact. This is why a poor response can indicate pituitary GH deficiency, making sermorelin useful as a diagnostic probe. KEGG identifies sermorelin as a GHRH analog targeting GHRHR, functioning as a GHRH-receptor agonist and diagnostic agent.
Molecular detail: GHRH-R is a class-B (secretin-family) GPCR coupled to Gs → adenylyl cyclase → cAMP → PKA, driving GH gene transcription and secretory-granule exocytosis. Sermorelin is the 1–29 fragment retaining full GHRH-receptor binding and functional potency. This is mechanistically distinct from the ghrelin-receptor (Gq/PLC/Ca²⁺) GHRPs — the two arms converge at the somatotroph, the basis of GHRH + GHRP synergy.
Grade B
📈
2 · Endogenous GH-pulse amplification
Instead of acting like external GH, sermorelin increases a natural GH signal — a rapid, transient secretory pulse.
Clinical significance: IV and SC administration increase plasma GH by stimulating pituitary release; early human GRF/GHRH studies showed clear GH peaks. A 50 µg IV bolus of GRF peptides in normal volunteers produced GH increases with maxima around 15–30 minutes. The pulse is brief, mirroring physiologic GH bursts rather than the sustained elevation of injected GH.
Molecular detail: The secretory response reflects PKA-driven exocytosis of pre-stored GH plus transcriptional upregulation, shaped by the prevailing somatostatin tone. Route/dose pharmacology in normal men compared IV, SC, and intranasal GHRH(1-29) GH responses. The short half-life (~11 min) means each dose produces a single discrete pulse rather than a plateau.
Grade B
🧬
3 · IGF-1 axis activation
Repeated GH stimulation can raise IGF-1, one of the main downstream growth-and-repair signals.
Clinical significance: Sustained nightly dosing translates discrete GH pulses into a measurable downstream signal. In age-advanced adults, nightly GHRH-analog administration increased serum IGF-1 and IGFBP-3 within weeks. IGF-1 is therefore the practical monitoring biomarker — and the parameter that should stay within the age-adjusted physiologic range.
Molecular detail: Pituitary GH activates hepatic and peripheral GH receptors → JAK2/STAT5 → IGF-1 transcription, while IGFBP-3 changes track somatotropic-axis activation. IGF-1/IGFBP-3 rose in the Khorram 1997 RCT, with a male-only lean-mass/insulin-sensitivity signal and transient hyperlipidemia. The magnitude depends on dose frequency and intact hepatic GH signaling.
Grade B/D
🔬
4 · Pituitary-reserve / diagnostic signaling
Sermorelin can help test whether the pituitary can still release GH — its original FDA-approved purpose.
Clinical significance: A provocative GH-stimulation test distinguishes pituitary (secondary) from hypothalamic causes of GH deficiency. IV sermorelin at 1 µg/kg has been described as a relatively rapid and specific diagnostic test for GH reserve. A positive response requires functional hypothalamic-pituitary-somatotroph machinery; a poor response implicates pituitary GH deficiency.
Molecular detail: Because sermorelin acts only at the pituitary GHRH-R, it isolates somatotroph capacity from upstream hypothalamic input — a cleaner pituitary probe than insulin-tolerance testing. This diagnostic use was the basis of Geref Diagnostic (NDA 19-863, approved 1990). Peak GH typically occurs 30–60 min post-injection.
Grade B
🌙
5 · Sleep-timed GH physiology
Night dosing is used because GH is naturally pulsatile and the largest pulses are sleep-linked.
Clinical significance: Dosing at bedtime aligns the induced pulse with the body's dominant nocturnal GH surge. Adult nightly GHRH-analog dosing at 2100 produced acute GH release within 10 minutes lasting around 2 hours, increasing nocturnal GH exposure. Notably, the same trial did not show improved subjective sleep quality — a useful corrective to "sleep-enhancement" marketing.
Molecular detail: GH is secreted episodically under reciprocal GHRH (stimulatory) and somatostatin (inhibitory) control, with the greatest output during slow-wave sleep. Endotext describes GH secretion as episodic, stimulated by GHRH and inhibited by somatostatin. Bedtime sermorelin reinforces, rather than replaces, this rhythm.
Grade D/P
♻️
6 · Feedback-limited stimulation vs direct GH
Sermorelin may be more self-limiting than injecting GH directly — but that does not make it risk-free.
Clinical significance: Because the effect depends on pituitary capacity and endogenous negative feedback, it is theoretically less likely than exogenous GH to produce sustained supraphysiologic GH/IGF-1. Label-derived information still notes GH/IGF-1-related lab increases and thyroid changes, and long-term carcinogenicity/fertility animal studies were not performed — so the safety advantage is mechanistic inference, not proven outcome data.
Molecular detail: Rising IGF-1 and somatostatin tone feed back to dampen further GHRH-driven release, capping the pulse. Anti-GRF antibodies occurred in many trial patients at least once, with unclear clinical significance. The feedback ceiling is real but not absolute — supraphysiologic IGF-1 is still achievable with aggressive dosing, which is why IGF-1 monitoring is required.
GHRH(1-29) + GHRP-2 co-administration studied for additive GH release in children
L3 · PK summary
Clinical pharmacokinetics (label-derived)
Parameter
Value
Note
Half-life (IV/SC)
≈ 11–12 min
Short; single discrete pulse per dose label monograph
SC peak (Tmax)
5–20 min after 2 mg SC
Rapid onset
SC absolute bioavailability
≈ 6%
Low — drives high SC doses vs IV
Adult clearance
≈ 2.4–2.8 L/min
Rapid systemic clearance
GH peak after dose
15–60 min
Diagnostic sampling window
Molecular weight
3357.9 Da (free base)
Acetate salt ≈ 3418 Da
03 · Dosing protocols & models
Route-specific dosing models.
Sermorelin has more dosing grounding than most peptides here — a discontinued FDA label, pediatric clinical trials, and a diagnostic-test protocol. But adult "wellness/optimization" dosing is an extrapolation, not a validated regimen. The models below separate label/clinical anchors from speculative adult practice patterns, working in micrograms (1 mg = 1000 µg). Compounded availability is not the same as FDA-approved marketed status.
Important · regulatory status
Sermorelin acetate was FDA-approved as Geref Diagnostic (NDA 19-863, 1990) for pituitary GH-reserve testing and as Geref (NDA 20-443, 1997) for pediatric idiopathic GH deficiency; EMD Serono discontinued both in 2008 for commercial reasons and FDA withdrew approval effective June 2009 — a Federal Register determination found it was NOT withdrawn for safety or effectiveness. The marketed product is discontinued; current availability is via 503A/503B compounding, which is not equivalent to FDA-approved finished-drug status. It is prohibited in sport at all times under WADA category S2 (GH-releasing factors). All adult wellness dosing is off-label and requires physician supervision.
PK / PD anchor
Label-derived clinical pharmacology reports SC peak concentrations 5–20 min after 2 mg SC, mean SC absolute bioavailability ~6%, adult clearance ~2.4–2.8 L/min, and a half-life of ~11–12 min after IV or SC dosing. The short half-life means each injection produces one discrete GH pulse — the rationale for once-nightly bedtime dosing that aligns with the dominant nocturnal GH surge.
Subcutaneous nightly model
Label-derived adult anchor · off-label wellness use is speculative
Not for active malignancy, uncontrolled diabetes, unexplained intracranial symptoms, pregnancy/lactation without specialist oversight, or WADA-tested athletes. Dose anchor exists, but wellness-style optimization is speculative. Grade D/B.
Dose bands · global
Global dose-band reference (working unit µg/day)
Band
µg/day
≈ µg/kg/day @ 70 kg
Basis
Low
100 µg/day
1.4
Conservative practice-pattern start; not label-specific
Standard
200–300 µg/day
2.9–4.3
Label-derived bedtime SC range
High / specialist
>300 µg/day
>4.3
Not routine; specialist/research justification only
Pediatric research
20–30 µg/kg/day
weight-based
Pediatric trials — not adult wellness extrapolation
Weight-band scaffold · SC
Weight-band interpolation (calculator scaffold, not a prescription)
Body weight
Low ~1.5 µg/kg
Standard ~3 µg/kg
Upper ~4 µg/kg
55 kg
83 µg
165 µg
220 µg
65 kg
98 µg
195 µg
260 µg
75 kg
113 µg
225 µg
300 µg
85 kg
128 µg
255 µg
340 µg
95 kg
143 µg
285 µg
380 µg
105 kg
158 µg
315 µg
420 µg
Titration logic · SC
Titration decision logic
Trigger
Action
Rationale
Injection-site pain / redness / swelling
Rotate site; hold if severe
Injection reactions were among the most common AEs
IGF-1 above age-adjusted range
De-escalate or hold
Indicates downstream GH-axis activation
New edema, carpal-tunnel, paresthesias
De-escalate / hold
GH/IGF-axis fluid-retention pattern
Fasting glucose / A1c worsens
Hold and evaluate
GH-axis can affect metabolic state
Headache, visual or neurologic symptoms
Hard stop + urgent eval
Do not attribute serious symptoms to peptide
Active cancer / unexplained mass
Avoid / hard stop
Growth-factor-axis concern
Untreated hypothyroidism
Correct thyroid first
Hypothyroidism can impair response
WADA-tested athlete
Avoid
GHRH analogs prohibited
Biomarker scaffold · SC
Biomarker monitoring scaffold
Marker
Use
Validated for sermorelin?
IGF-1
Downstream GH-axis activity
Partially (GHRH-analog studies)
GH stimulation response
Diagnostic pituitary reserve
Yes — diagnostic context (IV use)
Fasting glucose
Metabolic safety
No — safety scaffold
HbA1c
Longer-term glucose safety
No
TSH / free T4
Thyroid status
Partially (label precaution)
Lipid panel
Cardiometabolic context
No (transient hyperlipidemia reported)
BP / weight / edema
Clinical safety
No
Sleep quality
Outcome tracking
No (not improved in cited adult trial)
Pediatric weight-based research model
Specialist endocrinology only · not for adult wellness
Grade B
Evidence basis
Pediatric GH-deficiency / short-stature clinical studies — the basis of the original Geref therapeutic approval.
Clinical anchor
Once-daily 30 µg/kg SC increased height velocity in GH-deficient children (Thorner 1996).
Other anchors
Twice-daily 20 µg/kg SC studied in short children not GH-insufficient (Kirk 1994); 15 µg/kg BID for radiation-induced GHD (Ogilvy-Stuart 1997).
Escalation
Not generalized; depends on pediatric endocrinology diagnosis, growth velocity, bone age, IGF-1, and thyroid status.
Cycle length
Months to years in study contexts — not peptide-clinic "cycles."
Monitoring
Height velocity, bone age, IGF-1, thyroid, glucose, puberty status.
Pediatric dosing must not be generalized to adult wellness use, and must be managed by a pediatric endocrinologist. Grade B for studied pediatric contexts; D if extrapolated.
Pediatric anchors
Weight-based pediatric study doses
Study
Dose
Population
Grade
Thorner 1996
30 µg/kg once daily SC
GH-deficient children
B
Kirk 1994
20 µg/kg twice daily SC
Short children, not GH-insufficient
B
Ogilvy-Stuart 1997
15 µg/kg twice daily SC
Radiation-induced GHD
B
Pediatric monitoring
Pediatric endocrine monitoring
Measure
Purpose
Height velocity
Primary growth outcome
Bone age
Skeletal maturation tracking
IGF-1
Axis activation / dose response
Thyroid / glucose / puberty
Safety and confounders
Intravenous diagnostic challenge
Pituitary GH-reserve testing · original Geref Diagnostic use
Grade B/D
Evidence basis
Diagnostic pituitary-function testing — the FDA-approved Geref Diagnostic indication.
Dose anchor
1 µg/kg IV has been described as a rapid diagnostic GH-reserve test.
Timing
Serial GH sampling after the bolus (peak typically 15–60 min); exact protocol per lab/endocrine standard.
Should be performed in a supervised clinical/lab setting. Grade B/D.
Interpretation · diagnostic
Reading the GH-stimulation result
Pattern
Interpretation
Caveat
Robust GH peak
Intact somatotroph reserve
Assay- and cut-off-dependent
Blunted / flat peak
Suggests pituitary GH deficiency
Requires functional H-P-somatotroph axis
Discordant result
Repeat / alternative provocative test
No single test is definitive
Intranasal research / nonstandard route
Pharmacodynamic study only · not a validated dosing route
Grade D/P
Evidence basis
Human route-comparison pharmacodynamic study of IV/SC/intranasal GHRH(1-29) in normal men — route evidence, not a standard protocol.
Dose
Not established for clinical use.
Caution
Nasal peptide absorption is variable and far lower than SC; do not infer SC-equivalent dosing.
Investigational delivery only. Grade D/P.
Route note · intranasal
Why intranasal appears in the literature
Point
Detail
Grade
Route comparison
IV/SC/intranasal GH responses compared in normal men
B
Bioavailability
Nasal absorption variable, much lower than SC
P
Clinical dose
Not established
D
Oral route
Not established for native sermorelin
Grade P/D
Evidence basis
Not established for native sermorelin.
Dose
No validated oral sermorelin dose.
Rationale
Peptide degradation in the GI tract and poor oral bioavailability make oral use unsupported unless a specifically engineered formulation has evidence.
Of conceptual interest only. Grade P/D.
Oral feasibility
Why oral GHRH peptides fail
Barrier
Detail
Proteolysis
Gastric/intestinal peptidases degrade the 29-AA chain
Absorption
Large hydrophilic peptide, minimal passive uptake
Implication
SC is the practical route; oral needs engineered delivery
L2 · Reconstitution & dose math
Reconstitution & Dose Calculator
For reference only. Not medical dosing advice. Adult doses above 300 µg/day fall outside the label-derived range and should prompt specialist review. Verify peptide purity, sterility, and storage; only use product from a licensed source.
Concentration
—
Draw volume
—
Units (U-100)
—
Doses per vial
—
Basis
—
04 · Combination protocols
Stacking sermorelin.
Sermorelin's cleanest combination logic comes from its receptor: as a pure GHRH-receptor agonist, it pairs mechanistically with the ghrelin-receptor GHRPs (the two arms converge at the somatotroph) and with lifestyle levers on the GH axis. No combination has modern outcome-trial validation, and every GH-axis stack magnifies IGF-1 exposure. Combination use requires endocrine screening and physician oversight; sermorelin is WADA-prohibited for athletes.
GHRP / Ghrelin-Agonist Synergy
High Synergy
SermorelinGHRP-2GHRP-6 / Ipamorelin
The signature pairing. Sermorelin drives the GHRH-R (Gs–cAMP) arm; a GHRP drives the ghrelin-receptor (Gq/PLC/Ca²⁺) arm and blocks somatostatin — distinct mechanisms converging on the same somatotroph for a supra-additive pulse. GHRH(1-29) + GHRP-2 co-administration was studied for GH release in children with GH insufficiency and idiopathic short stature. Additive GH/IGF-1 exposure and anti-doping/compounding issues are the cautions. Not an approved protocol.
Component
Arm
Evidence
Sermorelin
GHRH-R · Gs–cAMP
B (GHRH arm)
GHRP-2 / -6 / ipamorelin
GHSR-1a · Gq/PLC
C/D (combo)
Sleep / Lifestyle Optimization
Moderate Synergy
SermorelinSleep hygieneBedtime dosing
GH secretion is sleep-linked and pulsatile, so bedtime dosing and good sleep hygiene may support physiologic GH rhythm. The caution is honesty: the cited adult RCT increased nocturnal GH exposure but did NOT show improved subjective sleep quality. Do not overstate sleep outcomes. Grade D.
Lever
Effect
Grade
Slow-wave sleep
Dominant physiologic GH pulse
A (physiology)
Bedtime sermorelin
Reinforces nocturnal GH
B (GH) / D (sleep outcome)
Resistance Training / Protein Adequacy
Moderate Synergy
SermorelinResistance trainingProtein ≥1.6 g/kg
GH/IGF-axis activation is often discussed alongside lean-mass goals. The supporting signal is modest and sex-specific: the Khorram adult GHRH-analog RCT showed a male-only lean-mass / insulin-sensitivity signal. Avoid in active malignancy or uncontrolled metabolic disease. Grade D.
Lever
Rationale
Grade
Resistance training
Independent lean-mass driver
A (physiology)
Sermorelin add-on
Male-only lean-mass signal
D
Thyroid Optimization (Prerequisite, Not Booster)
Safety Overlay
SermorelinTSH / free T4
Untreated hypothyroidism can blunt the GH response, so euthyroid status is a prerequisite — not a performance booster. Label-derived precautions note hypothyroidism can jeopardize response and recommend thyroid monitoring. Do not add thyroid hormone purely to "boost" peptide effect without a diagnosis. Grade D.
Step
Action
Baseline
Check TSH / free T4
If hypothyroid
Treat before sermorelin
GHRH-Analog Cross-Reference
Comparator
SermorelinTesamorelinCJC-1295
Alternatives rather than a stack. Tesamorelin is the FDA-approved, longer-acting GHRH analog (HIV lipodystrophy); CJC-1295 is the MOD GRF(1-29) backbone engineered for a longer half-life. CJC-1295 derives from modifying GRF(1-29) at residues 2/8/15/27. Stacking multiple GHRH analogs is redundant. Grade D.
Analog
Half-life
Status
Sermorelin
~11 min
Was approved (Geref)
Tesamorelin
~26–38 min
FDA-approved (Egrifta)
CJC-1295 (no DAC)
~30 min
Not approved
Hard-Constraint Note
Do Not Combine
Active malignancyIntracranial pathologyWADA testing
Avoid growth-axis stimulation stacks in active malignancy, unexplained masses, uncontrolled diabetes, active intracranial pathology, pregnancy/lactation without specialist oversight, or in WADA-tested athletes. WADA prohibits GHRH and analogues; the label did not study and did not recommend treatment in GHD secondary to intracranial lesions. These are absolute stop conditions.
Condition
Status
Active malignancy / pregnancy
Absolute avoid
Intracranial lesion GHD
Not recommended
WADA-tested athlete
Prohibited
Arginine Augmentation (Diagnostic Context)
Diagnostic Pairing
SermorelinL-Arginine
In the diagnostic setting — not wellness — arginine suppresses somatostatin tone and augments the GHRH-stimulated GH response, improving test specificity. Adult data indicate sermorelin + arginine is a more specific GH-reserve test. This is a diagnostic protocol pairing, not a therapeutic stack, and belongs in a supervised testing context.
Agent
Role
Grade
Sermorelin
GHRH-R stimulation
B (Dx)
L-Arginine
Somatostatin suppression
B (Dx)
Glycemic-Safety Co-Management
Safety Overlay
SermorelinGlucose / A1cIGF-1
Because GH-axis stimulation can affect insulin sensitivity, glycemic and IGF-1 monitoring is the rational overlay rather than a peptide partner. Keep IGF-1 within the age-adjusted physiologic range and watch fasting glucose/A1c. Not a pharmacologic stack; Grade D as a "protocol."
Marker
Purpose
Grade
IGF-1
Keep physiologic; over-stimulation guard
D
Glucose / A1c
Insulin-resistance surveillance
D
Clinical note — Sermorelin's strongest combination rationale is dual-arm GH-secretagogue synergy with a GHRP, where the GHRH and ghrelin pathways reinforce each other at the somatotroph — but this is exactly where additive IGF-1 exposure compounds. No combination has modern outcome validation. The safest "stack" is a euthyroid baseline plus an IGF-1/glucose monitoring overlay layered onto physician-supervised, time-limited use, with avoidance entirely in the oncologic, intracranial, and metabolic risk groups.
05 · Safety & contraindications
Safety profile & contraindications.
Sermorelin has a decades-long clinical safety record from its Geref era, which is reassuring relative to gray-market peptides. The dominant signals are injection-site reactions, the general GH/IGF-axis adverse pattern (IGF-1 elevation, edema, glucose effects), thyroid-status dependence, and immunogenicity (anti-GRF antibodies of unclear significance). Long-term carcinogenicity/fertility animal studies were never performed.
Elevated IGF-1Downstream GH-axis stimulation may push IGF-1 above the age-adjusted range. Monitor and keep physiologic. Grade D.
Edema / nerve-compression symptomsGH-axis activation can create fluid-retention-like effects (carpal-tunnel, paresthesias) by class analogy. Grade D/P.
Glucose changesGH biology interacts with insulin sensitivity and glucose handling; monitor in metabolic risk. Grade D.
Immunogenicity (anti-GRF antibodies)Anti-GRF antibodies occurred in many patients at least once, with unclear clinical significance. Grade D.
GI / urticaria / dysgeusiaNausea, vomiting, urticaria, dysgeusia, pallor, chest tightness reported in label AE set.
Malignancy concernGrowth-factor signaling is theoretically undesirable in active malignancy — a hard avoid. Grade D/P.
Intracranial-lesion GHDPatients with GHD secondary to intracranial lesion were not studied; treatment not recommended in that group. Grade D.
Monitoring scaffold
Baseline
IGF-1, fasting glucose, HbA1c, TSH/free T4, lipid panel, BP, weight. Pregnancy test if reproductive potential. Cancer-screening status current. Pituitary imaging if an intracranial lesion is suspected. Document WADA status for athletes.
During use
IGF-1 at 6–8 weeks then every 8–12 weeks (hold/decrease if above age-adjusted range); fasting glucose/A1c at 8–12 weeks; TSH/free T4 periodically; lipid panel at 12–16 weeks; BP/weight/edema and injection sites each check-in. None of these thresholds is validated specifically for adult sermorelin optimization.
Stop / escalate triggers
Hard-stop on pregnancy, active malignancy/unexplained mass, intracranial symptoms (headache/visual change), or WADA-tested status. De-escalate on IGF-1 above range, new edema/carpal-tunnel, worsening glucose, or severe injection reactions. Correct hypothyroidism before continuing.
Contraindications & cautions
Condition
Concern
Severity · grade
Known hypersensitivity to sermorelin/excipients
Label contraindication
High
Active malignancy
Growth-factor-axis concern
High
Unexplained mass / abnormal cancer screening
Risk unresolved
High
Intracranial lesion-related GHD
Not studied / not recommended
High
Pregnancy
No adequate controlled studies
High
Breastfeeding
Unknown excretion in milk
Moderate–High
Untreated hypothyroidism
Can jeopardize response
Moderate
Uncontrolled diabetes
GH-axis metabolic concern
Moderate–High
Severe edema / carpal-tunnel symptoms
Possible GH-axis intolerance
Moderate
WADA-tested athlete
Prohibited substance class
High
Active intracranial pathology (any)
Symptom-masking / axis concern
High
Pre-diabetes / insulin resistance
Glycemic worsening
Caution
Prior GH-axis tumor (acromegaly)
Further GH stimulation
Avoid
Non-sterile / unverified compounded product
Endotoxin / impurity / immunogenicity risk
Avoid
Pediatric use outside specialist care
Growth-axis manipulation
High
Active intracranial hypertension / headache disorder
Symptom-masking concern
Caution
Acromegaly / prior GH-axis tumor
Further GH stimulation undesirable
Avoid
Proliferative diabetic retinopathy
Growth-factor concern
High
Carpal-tunnel / peripheral neuropathy history
GH/IGF fluid-tissue effects
Monitor
Severe renal / hepatic impairment
Altered clearance; limited data
Caution
06 · Trials & evidence base
What the evidence actually shows.
Sermorelin has stronger human pharmacology and pediatric endocrine evidence than most gray-market peptides because it had a genuine drug-product history and clinical trials. The best-supported claims are GHRH-receptor agonism, pituitary GH release, GH/IGF-axis activation, pediatric growth contexts, and diagnostic pituitary-reserve testing. Evidence for adult anti-aging, body-composition, or sleep claims is much thinner and remains speculative.
FDA approval · 1990/97
Geref
Approved as Geref Diagnostic (1990, pituitary testing) and Geref (1997, pediatric GHD); discontinued 2008 for commercial reasons. Federal Register.
Khorram: nightly GHRH analog ×16 wk in adults 55–71 raised IGF-1/IGFBP-3; male-only lean-mass signal. Adult axis activation.
Diagnostic · 1999
1 µg/kg IV
Prakash & Goa review: IV 1 µg/kg as a rapid, specific GH-reserve test in children. Diagnostic use.
B/DClinical review · diagnosis/treatment
Prakash & Goa 1999 — sermorelin in pediatric GH deficiency
Comprehensive review summarizing sermorelin's use in the diagnosis (IV 1 µg/kg GH-reserve test) and treatment of children with idiopathic GH deficiency — the clinical synthesis underpinning the Geref era.
Thorner et al. 1996 — once-daily SC sermorelin in GH-deficient children
Once-daily 30 µg/kg SC increased height velocity in GH-deficient children — the pivotal pediatric efficacy data supporting the therapeutic Geref approval.
Khorram et al. 1997 — GHRH(1-29) in age-advanced adults
Single-blind, placebo-controlled study in 19 adults aged 55–71: 10 µg/kg nightly SC for 16 weeks activated the GH/IGF axis (IGF-1, IGFBP-3 rose), with male-only lean-mass/insulin-sensitivity/QOL signals and transient hyperlipidemia. No subjective sleep-quality improvement.
Vance et al. 1986 — IV / SC / intranasal GHRH(1-29) in normal men
Route- and dose-comparison study of GH-secretory responses to GHRH(1-29) by IV, SC, and intranasal administration — the basis for understanding sermorelin's route-dependent pharmacodynamics and low intranasal bioavailability.
Losa et al. 1984 — GH stimulation with pancreatic GRF
Early human pharmacodynamic study: a 50 µg IV bolus of GRF peptides in normal volunteers produced GH increases peaking around 15–30 minutes, with no serious side effects recorded — foundational evidence for the GRF/GHRH secretagogue effect.
Ogilvy-Stuart et al. 1997 — GHRH(1-29) in radiation-induced GHD
Multicenter study: 15 µg/kg twice daily SC for one year in radiation-induced GH deficiency, comparing growth before and after treatment — evidence in an acquired-GHD population.
Tuilpakov et al. 1995 — GHRH(1-29) + GHRP-2 combination
Studied the GH-releasing interaction between GHRH(1-29) and GHRP-2 in children with GH insufficiency and idiopathic short stature — direct human evidence for the two-arm secretagogue synergy concept.
Authoritative database annotation mapping sermorelin as a GHRH analog targeting GHRHR, with efficacy as a diagnostic/pituitary-function agent — the molecular identity and receptor-target reference.
Reference physiology: GH is secreted episodically under reciprocal control by GHRH (stimulatory) and somatostatin (inhibitory), with the largest pulses during slow-wave sleep — the framework that makes bedtime sermorelin dosing rational.
FDA Federal Register — Geref not withdrawn for safety/efficacy
The 2013 Federal Register determination confirms Geref (NDA 19-863 Dx 1990; NDA 20-443 Rx 1997) was discontinued by EMD Serono in 2008 and withdrawn in 2009 for commercial — not safety or effectiveness — reasons, keeping a compounding pathway open.
Drug-monograph source for the PK (half-life ~11–12 min, SC bioavailability ~6%, clearance ~2.4–2.8 L/min), the adverse-event set, the thyroid and intracranial-lesion precautions, and the toxicology gaps (no long-term carcinogenicity/fertility studies).
Wilton et al. 1993 — GHRH(1-29) PK, IV vs intranasal in 30 men
IV doses as low as 0.25 µg/kg released GH; maximal release at 1–2 µg/kg. Despite rapid IV elimination, GH stayed elevated ~3 hours. Intranasal bioavailability was only 3–5%, and ~50 µg/kg intranasal ≈ 1 µg/kg IV — quantifying why injection is the practical route.
IV sermorelin 1 µg/kg is a rapid, relatively specific GH-reserve test with fewer false positives than some provocative tests; adult data suggest sermorelin + arginine is more specific. A normal response cannot exclude GHD of hypothalamic origin — a key interpretive caveat.
Ishida et al. 2020 — GH secretagogues: history & mechanism
Places sermorelin in the GHRH-receptor-agonist branch of the GH-secretagogue family (distinct from the ghrelin/GHS-R agonists), tracing the development arc from native GHRH through the 1-29 fragment to the clinically tested analogs. GHS history & pharmacology review.
Hümmelink et al. 1993 — intranasal GHRH(1-29) in short children
A 6-month intranasal pilot in short prepubertal children showed initial GH peaks but declining absorption/effectiveness, emerging GHRH antibodies, and local nasal reactions — concluding the intranasal form was unsuitable, reinforcing SC as the viable route.
GRADE summary — Sermorelin earns Grade B for GHRH-receptor agonism, pituitary GH release, GH/IGF-axis activation, pediatric growth contexts, and diagnostic pituitary-reserve testing — backed by a genuine drug-product history and human trials. Adult wellness, anti-aging, body-composition, sleep-enhancement, and broad "recovery" claims remain D/P speculative, with the cited adult RCT notably failing to improve subjective sleep quality. What is missing: modern large adult outcome RCTs, standardized adult dosing trials, long-term safety data, and validated wellness biomarker thresholds. Honest positioning: "a GHRH-receptor agonist with real pharmaceutical pedigree for pediatric/diagnostic use, repurposed off-label for adult optimization on much thinner evidence."
07 · Compare & contrast
Sermorelin vs the secretagogue field.
Sermorelin is the GHRH-receptor anchor of the class: physiologic, feedback-preserved, and the only one with FDA-approval pedigree — but short-acting. Tesamorelin is the FDA-approved, longer-acting GHRH analog with outcome data; CJC-1295 is the engineered long-half-life GHRH backbone; the GHRPs (ipamorelin, GHRP-2/-6) work through the complementary ghrelin-receptor arm.
L1 · Consumer — Sermorelin is a small synthetic peptide that signals the pituitary gland to release more of the body's own growth hormone. It is not the same as injecting growth hormone directly. It was once an FDA-approved medicine (Geref) for children, but most modern adult wellness uses should be treated as experimental and off-label.
L2 · Clinical — Sermorelin is the 1–29 active fragment of human GHRH and functions as a GHRH-receptor agonist, producing feedback-limited, physiologic GH pulses. Its best-supported uses are pituitary GH-reserve testing and historical pediatric growth contexts; adult optimization protocols require endocrine screening, IGF-1/glucose/thyroid monitoring, and conservative claims. Short half-life (~11 min) drives once-nightly bedtime dosing.
L3 · Research — Sermorelin activates GHRHR on anterior pituitary somatotrophs (Gs–cAMP–PKA), producing rapid GH secretory pulses and downstream IGF-1/IGFBP-3 changes when pituitary reserve is intact. Its short half-life, ~6% SC bioavailability, feedback-limited axis dependence, immunogenicity (anti-GRF antibodies), and thyroid/metabolic considerations define the translational boundary between endocrine pharmacology and speculative peptide-clinic protocols — and motivated the longer-acting analogs (MOD GRF/CJC-1295, tesamorelin).
08 · References & evidence
Source register.
Evidence grades reflect the strength of support for the specific claim cited, not the prestige of the journal. Sermorelin's pediatric trials, adult GHRH-analog RCT, diagnostic-use review, and regulatory record are its firmest evidence; database and label sources anchor identity, pharmacology, and the precaution set.
A · RCT / regulatory approval
B · Human clinical / pharmacology study
C · Small / exploratory human
D · Database / regulatory / label / practice-pattern